Cogstate Ltd · ASX:CGS
Cogstate — Non-Deal Roadshow (October 2009)
16 slides from Cogstate's roadshow presentation, Oct 22, 2009
Slide 1: Roadshow Presentation October 2009
For personal use only Roadshow Presentation October 2009 www.cogstate.com
Slide 2: Company overview and key highlights
Company overview and key highlights • CogState (ASX: CGS) is a profitable health services, technology and For personal use only equipment company that provides cognition-testing software to pharmaceutical companies undertaking clinical trials • Cognition testing is used in many clinical trials for d
Slide 3: Financial Summary
Financial Summary Share price $0.26 Major Shareholders Shares Held (%) For personal use only Market cap (as at 1/10/09) $17.1 m Martyn Myer 13,000,000 19.80 Cash & Debtors $4.1 m GBS Venture Management Pty Ltd 9,137,535 13.92 Asia Union Investments Pty Ltd 6,000,000 9.14 52 week high $0.30 Citicorp
Slide 4: The CogState advantage
The CogState advantage • Validity of tests confirmed in over 150 peer-reviewed scientific articles For personal use only • CogState experts have published over 300 journal articles, co-authored numerous book chapters, and edited and authored textbooks and handbooks in neuroscience and neuropsycholog
Slide 5: Growing computerised testing market
Growing computerised testing market • CNS disorders contribute up to 35% of disease burden in major pharma markets and is a key focus for big pharma R&D For personal use only • 12 major pharma companies: ~163 ongoing trials within CNS portfolio at various stages of development (Phase 1 to Phase 3) •
Slide 6: Profit driven by strong sales growth
For personal use only Profit driven by strong sales growth www.cogstate.com
Slide 7: Lower A$ helped boost sales revenue
For personal use only Lower A$ helped boost sales revenue www.cogstate.com
Slide 8: Larger clinical trials increase value of sales contracts
Larger clinical trials increase value of sales contracts For personal use only www.cogstate.com
Slide 9: Strong trading conditions producing contract growth
Strong trading conditions producing contract growth • September quarter – revenue and cash receipts on target For personal use only – strong interest from new and existing customer base – US$3.18m (A$3.73m) contracts in Q1 www.cogstate.com
Slide 10: Contracted future revenue on the rise
Contracted future revenue on the rise • Contracted future revenue is secured by a signed sales contract and will be recognised as revenue upon achievement of a For personal use only milestone at a future point in time • 75% growth in contracted future revenue – 30-Sep-09: US$4.9m (or A$5.3m at US$0.
Slide 11: H1 revenue growth despite high A$
H1 revenue growth despite high A$ • H1 revenue forecast to be in range of US$4.0 – US$4.2m For personal use only • The prevailing exchange rates will impact on the amount of A$ revenue recognised Forecast US$4.0m - US$4.2m At US$0.92 exchange rate A$4.63m - A$4.75m At US$0.96 exchange rate A$4.52m -
Slide 12: US$ revenue growth on target
For personal use only US$ revenue growth on target www.cogstate.com
Slide 13: FY 2010: H1 Profit Guidance
FY 2010: H1 Profit Guidance Strengthening A$ will impact revenue and profitability For personal use only H1 Forecasts: Half Year (H1) Forecast US$0.92 US$0.96 $‘000,000 $’000,000 $’000,000 $’000,000 US$ revenue US$4.0 - US$4.2 US$4.0 - US$4.2 A$ revenue A$4.63 - A$4.75 A$4.52 - A$4.64 Operating Prof
Slide 14: Half Year Profit Comparison (at US$0.92)
Half Year Profit Comparison (at US$0.92) Half Year Results Jul 08 – Jan 09 – Jul 09 – Dec 08 Jun 09 Dec 09 For personal use only (Forecast) $’000,000 $’000,000 $’000,000 US$ revenue US$2.94 US$3.30 US$4.20 Average rate of conversion US$0.76 US$0.73 US$0.88 A$ Revenue A$3.87 A$4.52 A$4.75 Operating P
Slide 15: Is the growth sustainable?
Is the growth sustainable? • Increased use of CogState in phase 2 and 3 clinical trials – Larger contracts over longer time period, providing greater certainty of For personal use only contracted revenue from future periods • Cognition continues to be an area of focus in many indications, but partic
Slide 16: Brad O'Connor, Chief Executive Officer
For personal use only Brad O’Connor Chief Executive Officer CogState Ph: 03 9664 1300 boconnor@cogstate.com www.cogstate.com